Allogeneic hematopoietic stem cell transplantation in a prior lung transplant recipient

被引:0
作者
Fujiwara, Yuki [1 ]
Matsuoka, Ken-ichi [1 ]
Iwamoto, Miki [1 ]
Sumii, Yuichi [1 ]
Abe, Masaya [1 ]
Mizuhara, Kentaro [1 ]
Urata, Tomohiro [1 ]
Saeki, Kyosuke [1 ]
Meguri, Yusuke [1 ]
Asada, Noboru [1 ]
Ennishi, Daisuke [1 ]
Nishimori, Hisakazu [1 ]
Fujii, Keiko [1 ]
Fujii, Nobuharu [1 ]
Sugita, Junichi [2 ]
Kobayashi, Hajime [3 ]
Oto, Takahiro [4 ]
Maeda, Yoshinobu [1 ]
机构
[1] Okayama Univ Hosp, Dept Hematol & Oncol, Kita Ku, 2-5-1 Shikatacho, Okayama, Okayama 7008558, Japan
[2] Hokkaido Univ Hosp, Dept Hematol, Sapporo, Hokkaido, Japan
[3] Obihiro Kosei Hosp, Dept Hematol, Obihiro, Hokkaido, Japan
[4] Okayama Univ Hosp, Dept Organ Transplant Ctr, Okayama, Japan
基金
日本学术振兴会;
关键词
Myelodysplastic syndromes; Lung transplant; Allogeneic hematopoietic stem cell transplantation; Transplant tolerance; MYELOID NEOPLASMS; CORD BLOOD; RISK;
D O I
10.1007/s12185-020-02967-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hematological diseases after solid organ transplant (SOT) are an emerging issue as the number of long-term SOT survivors increases. Expertise in managing patients requiring allogeneic hematopoietic stem cell transplantation (HSCT) after SOT from independent donors is needed; however, clinical reports of HSCT after SOT are limited, and the feasibility and risk are not well understood. In particular, HSCT in prior lung transplant recipients is thought to be complicated as the lung is immunologically distinct and is constantly exposed to the surrounding environment. Herein, we describe a case of successful HSCT in a patient with myelodysplastic syndromes who had previously received a lung transplant from a deceased donor for bronchiolitis obliterans syndrome. Reports about cases of HSCT after lung transplant are quite rare; thus, we discuss the mechanisms of immune tolerance through the clinical course of our case. This case suggests that HSCT after SOT can be considered a therapeutic option in cases where the transplanted organ is functionally retained and the hematological disease is in remission.
引用
收藏
页码:871 / 877
页数:7
相关论文
共 50 条
  • [41] Feasibility of allogeneic hematopoietic stem cell transplantation in advanced age
    Fernandez-Luis, Sara
    Lamas, David Gomez
    Martin, Juan Manuel Cerezo
    Barrios, Juan Manuel Mora
    Segundo, Lucrecia Yanez San
    Escamilla, Miriam Sanchez
    Fernandez-Escalada, Noemi
    Sanchez, Jose Alvaro Calvo
    Garcia, Sergio Fernandez
    Dominguez-Garcia, Juan Jose
    Araujo, Mercedes Colorado
    Lopez-Duarte, Monica
    Martin-Sanchez, Guillermo
    Gaminde, Andres Insunza
    Alonso, Jose Inigo Romon
    Rubio, Rocio Lobeira
    Rodriguez, Jose Luis Arroyo
    Ciller, Beatriz Rueda
    Fernandez, Mar Hermosilla
    Betes, Victor Marco
    Ocio, Enrique Maria
    Rodriguez, Arancha Bermudez
    ANNALS OF HEMATOLOGY, 2024, 103 (02) : 583 - 591
  • [42] Feasibility of allogeneic hematopoietic stem cell transplantation in advanced age
    Sara Fernandez-Luis
    David Gomez Lamas
    Juan Manuel Cerezo Martin
    Juan Manuel Mora Barrios
    Lucrecia Yañez San Segundo
    Miriam Sanchez Escamilla
    Noemi Fernandez-Escalada
    Jose Alvaro Calvo Sanchez
    Sergio Fernandez Garcia
    Juan Jose Dominguez-Garcia
    Mercedes Colorado Araujo
    Monica Lopez-Duarte
    Guillermo Martin-Sanchez
    Andres Insunza Gaminde
    Jose Iñigo Romon Alonso
    Rocio Lobeira Rubio
    Jose Luis Arroyo Rodriguez
    Beatriz Rueda Ciller
    Mar Hermosilla Fernandez
    Victor Marco Betes
    Enrique Maria Ocio
    Arancha Bermudez Rodriguez
    Annals of Hematology, 2024, 103 : 583 - 591
  • [43] Allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma
    Firsova, Maiia, V
    Mendeleeva, Larisa P.
    Parovichnikova, Elena N.
    Solovev, Maksim, V
    Kuzmina, Larisa A.
    Risinskaya, Natalia, V
    Abramova, Tatiana, V
    Galtseva, Irina, V
    Savchenko, Valerii G.
    TERAPEVTICHESKII ARKHIV, 2021, 93 (07) : 778 - 784
  • [44] Significance of graft quality in allogeneic hematopoietic stem cell transplantation
    Jinca, Cristian
    Arghirescu, Smaranda
    Oprisoni, Andrada
    Balint-Gib, Loredana
    Baica, Mihaela
    Serban, Margit
    REVISTA ROMANA DE MEDICINA DE LABORATOR, 2009, 16 (03): : 21 - 27
  • [45] Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation
    Yingxue Lu
    Xiaojing Ma
    Jie Pan
    Rongqiang Ma
    Yujie Jiang
    Lipids in Health and Disease, 21
  • [46] ROLE OF THE INTENSIVE CARE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Shchekina, A. E.
    Galstyan, G. M.
    Drokov, M. Y.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2022, 67 (02): : 216 - 239
  • [47] Graft failure after allogeneic hematopoietic stem cell transplantation
    Ozdemir, Zehra Narli
    Bozdag, Sinem Civriz
    TRANSFUSION AND APHERESIS SCIENCE, 2018, 57 (02) : 163 - 167
  • [48] Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation
    Lu, Yingxue
    Ma, Xiaojing
    Pan, Jie
    Ma, Rongqiang
    Jiang, Yujie
    LIPIDS IN HEALTH AND DISEASE, 2022, 21 (01)
  • [49] Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation
    Smith, Patrick J.
    Lew, Meagan
    Lowder, Yen
    Romero, Kristi
    Thompson, Jillian C.
    Bohannon, Lauren
    Pittman, Alyssa
    Artica, Alexandra
    Ramalingam, Sendhilnathan
    Choi, Taewoong
    Gasparetto, Cristina
    Horwitz, Mitchell
    Long, Gwynn
    Lopez, Richard
    Rizzieri, David
    Sarantopoulos, Stefanie
    Sullivan, Keith
    Chao, Nelson
    Sung, Anthony D.
    BONE MARROW TRANSPLANTATION, 2022, 57 (01) : 89 - 94
  • [50] Subsequent malignancies after allogeneic hematopoietic stem cell transplantation
    Gunduz, Mehmet
    Ozen, Mehmet
    Sahin, Ugur
    Toprak, Selami Kocak
    Bozdag, Sinem Civriz
    Yuksel, Meltem Kurt
    Arslan, Onder
    Ozcan, Muhit
    Demirer, Taner
    Beksac, Meral
    Ilhan, Osman
    Gurman, Gunhan
    Topcuoglu, Pervin
    CLINICAL TRANSPLANTATION, 2017, 31 (07)